Integer (NYSE:ITGR) FY Conference Transcript

Integer Holdings Corporation (NYSE: ITGR) FY Conference Summary Company Overview - Integer is a leading medical device contract development and manufacturing organization, serving large MedTech companies and emerging customers globally [2][3] - In 2025, Integer reported revenues of approximately $1.85 billion, with 60% from cardiovascular business and 36% from cardiac rhythm management [3][5] Core Business Insights - Integer operates as a one-stop shop for customers, providing a deep breadth of products and vertical integration to simplify supply chains and enhance margins [4][5] - The company has a proven track record of performance, executing a strategy over the past eight to nine years that positions it well within the MedTech ecosystem [5][6] Growth Markets and Strategies - Key growth markets include electrophysiology, structural heart, neurovascular, and neuromodulation, with a focus on building critical capabilities through dedicated growth teams [8][9] - Investments in rapid prototyping and complex manufacturing capabilities are aimed at helping customers bring products to market faster [10][11] - Integer maintains a healthy pipeline of acquisition targets to enhance capabilities and vertical integration [12] Financial Performance and Outlook - Integer has experienced a 12% CAGR from 2022 to 2025, with adjusted operating income expanding by nearly 400 basis points [24] - For 2026, the company anticipates flat to 3% organic growth, with adjusted EBITDA expected to range from -3% to +3% due to headwinds from three specific products [26][27] - The company expects to return to above-market performance in 2027, with a target of 200 basis points above market growth [25][30] Customer Relationships and Market Position - Integer works with approximately 40 emerging innovators, particularly in the neuromodulation space, with expectations of high teens CAGR growth in this segment [20][21] - The company emphasizes customer success as a key focus area, recognizing that operational excellence and leadership development are critical for long-term growth [21][22] Capital Management and M&A Strategy - Integer has a disciplined capital management approach, prioritizing organic investments and targeted tuck-in acquisitions, with a $200 million share repurchase program authorized [22][23][48] - The M&A landscape remains robust, with a strong pipeline of opportunities in the markets of interest [50][51] Key Challenges and Market Dynamics - The company faces headwinds from three products that are expected to impact performance in 2026, but these are not due to competitive losses [36][37] - The electrophysiology market is expected to grow in the mid-teens despite these challenges, supported by a strong portfolio and exposure to PFA technology [43][44] Conclusion - Integer Holdings Corporation has built a strong business with a robust pipeline and a commitment to customer success, expecting to navigate current challenges and return to above-market performance in the coming years [30][52]